App 4D and Financial Report Half Year ended 30 Sep 2021
Filed with ASX · · 22 pages · English
This ASX announcement is authorised for release by the Board. - End - For Further Information Dr. John Lambert CEO and Managing Director john@ampliatx.com www.ampliatx.com About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important targe
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Inhibition of FAK by AMP945 in Phase 1 Clinical Trial
- Capital Raising Investor Presentation
- Entitlement Offer Prospectus
- Placement and Underwritten Entitlement Offer to Raise $12.4m
- Quarterly Activities and Cashflow Reports - Sep 2021 Qtr
Later from Amplia Therapeutics
- Amplia Awarded $2.1M R&D Cash Flow Loan
- Entitlement Offer Completed
- Amplia Provides Updated Investor Presentation
- Amplia Completes Manufacture of AMP945 for Planned Trials
- Quarterly Activities and Cashflow Reports - Dec 2021 Qtr
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics